# Mapping clinical outcomes to generic preference-based outcome measures: development and comparison of methods

## Mónica Hernández Alava,<sup>1\*</sup> Allan Wailoo,<sup>1</sup> Stephen Pudney,<sup>1</sup> Laura Gray<sup>1</sup> and Andrea Manca<sup>2</sup>

<sup>1</sup>School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK <sup>2</sup>Centre for Health Economics, University of York, York, UK

\*Corresponding author monica.hernandez@sheffield.ac.uk

Declared competing interests of authors: none

Published June 2020 DOI: 10.3310/hta24340

## **Plain English summary**

Developing and comparing mapping methods Health Technology Assessment 2020; Vol. 24: No. 34 DOI: 10.3310/hta24340

NIHR Journals Library www.journalslibrary.nihr.ac.uk

# **Plain English summary**

C oherent decisions about which health services and treatments to provide rely on economic analysis to weigh potential health benefits against costs. For decisions to be consistent across the whole health service, benefits need to be counted in the same way for patients with different health problems. This is accomplished by using a unit of measurement for treatment outcomes called the quality-adjusted life-year. The best way to calculate quality-adjusted life-years is to ask patients taking part in clinical studies to fill in specially designed questionnaires to describe their health in a simple, standardised way. However, clinical trials often record patient outcomes in different ways, leaving economic analysts without the necessary information to calculate quality-adjusted life-years. A way to overcome this problem (known as 'statistical mapping') is to use the available clinical data to predict the responses that would have been made by trial participants to the standard questionnaire. This requires analysis of data from an additional study in which patients have provided both types of outcome data to construct a statistical 'mapping model'.

Mapping is widely used in practice, but it is often based on simple mapping models that in some circumstances systematically mispredict and may consequently give a false picture of the real health benefits of treatments. This is important because it influences decisions about which treatments are available in the NHS; it has real effects on patients, clinicians, industry and the general public.

Our objectives are to develop promising new statistical mapping models specifically designed for different clinical contexts and to compare them using patient data in different disease areas. We have also developed an approach for judging the outcome of a mapping study. We find that the new methods work better than existing methods in terms of their ability to fit the data and avoid systematic bias.

### **Health Technology Assessment**

ISSN 1366-5278 (Print)

ISSN 2046-4924 (Online)

Impact factor: 3.819

Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, the Cochrane Library and Clarivate Analytics Science Citation Index.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: journals.library@nihr.ac.uk

The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

#### Criteria for inclusion in the Health Technology Assessment journal

Reports are published in *Health Technology Assessment* (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in *Health Technology Assessment* are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

#### **HTA programme**

Health Technology Assessment (HTA) research is undertaken where some evidence already exists to show that a technology can be effective and this needs to be compared to the current standard intervention to see which works best. Research can evaluate any intervention used in the treatment, prevention or diagnosis of disease, provided the study outcomes lead to findings that have the potential to be of direct benefit to NHS patients. Technologies in this context mean any method used to promote health; prevent and treat disease; and improve rehabilitation or long-term care. They are not confined to new drugs and include any intervention used in the treatment, prevention or diagnosis of disease.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

#### **This report**

The research reported in this issue of the journal was funded by the HTA programme as project number 15/141/09. The contractual start date was in September 2014. The draft report began editorial review in May 2019 and was accepted for publication in November 2019. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.

© Queen's Printer and Controller of HMSO 2020. This work was produced by Hernández Alava *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).

### Editor-in-Chief of Health Technology Assessment and NIHR Journals Library

Professor Ken Stein Professor of Public Health, University of Exeter Medical School, UK

### NIHR Journals Library Editors

**Professor John Powell** Chair of HTA and EME Editorial Board and Editor-in-Chief of HTA and EME journals. Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Senior Clinical Researcher, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

**Professor Andrée Le May** Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals) and Editor-in-Chief of HS&DR, PGfAR, PHR journals

**Professor Matthias Beck** Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

Dr Tessa Crilly Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin Senior Scientific Advisor, Wessex Institute, UK

Dr Peter Davidson Consultant Advisor, Wessex Institute, University of Southampton, UK

Ms Tara Lamont Director, NIHR Dissemination Centre, UK

Dr Catriona McDaid Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

Professor William McGuire Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads Professor of Wellbeing Research, University of Winchester, UK

Professor John Norrie Chair in Medical Statistics, University of Edinburgh, UK

**Professor James Raftery** Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

Professor Jonathan Ross Professor of Sexual Health and HIV, University Hospital Birmingham, UK

**Professor Helen Snooks** Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Ken Stein Professor of Public Health, University of Exeter Medical School, UK

**Professor Jim Thornton** Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Professor Martin Underwood Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of editors: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk